Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate ADAP funding bill to hit floor Sept. 2 as part of Labor/HHS Appropriations bill.

Executive Summary

SENATE ADAP FUNDING BILL TO HIT FLOOR SEPT. 2 as part of the Labor & HHS appropriations bill scheduled for floor consideration following the August Congressional recess. The House Labor/HHS appropriations bill is scheduled to reach the floor the second week of September. The Senate bill (S 1061) allocates $217 mil. for AIDS Drug Assistance Programs, while the House bill (HR 2264) affords ADAPs with $299 mil. While both appropriations are substantially higher than the Clinton Administration's FY 1998 budget request of $167 mil. for the program, the Administration is supporting the higher amount included in the House bill; the ADAP Working Group, composed of AIDS advocacy groups and pharmaceutical companies, predicted in an April report that state ADAPs would need $299 mil. in federal support during fiscal 1998 ("The Pink Sheet" April 21, T&G-5).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel